- Home
- CYH vs EYPT Comparison
CYH vs EYPT Comparison
Compare CYH & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- EYPT
- Stock Information
- Founded
- CYH 1985
- EYPT 1987
- Country
- CYH United States
- EYPT United States
- Employees
- CYH N/A
- EYPT N/A
- Industry
- CYH Hospital/Nursing Management
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- CYH Health Care
- EYPT Industrials
- Exchange
- CYH Nasdaq
- EYPT Nasdaq
- Market Cap
- CYH 410.5M
- EYPT 741.0M
- IPO Year
- CYH 1991
- EYPT 2005
- Fundamental
- Price
- CYH $4.10
- EYPT $11.95
- Analyst Decision
- CYH Hold
- EYPT Strong Buy
- Analyst Count
- CYH 8
- EYPT 6
- Target Price
- CYH $3.66
- EYPT $25.83
- AVG Volume (30 Days)
- CYH 2.2M
- EYPT 1.5M
- Earning Date
- CYH 10-23-2025
- EYPT 10-31-2025
- Dividend Yield
- CYH N/A
- EYPT N/A
- EPS Growth
- CYH N/A
- EYPT N/A
- EPS
- CYH 2.47
- EYPT N/A
- Revenue
- CYH $12,644,000,000.00
- EYPT $51,898,000.00
- Revenue This Year
- CYH N/A
- EYPT N/A
- Revenue Next Year
- CYH $2.46
- EYPT N/A
- P/E Ratio
- CYH $1.66
- EYPT N/A
- Revenue Growth
- CYH 0.74
- EYPT 2.99
- 52 Week Low
- CYH $2.24
- EYPT $3.91
- 52 Week High
- CYH $4.89
- EYPT $14.91
- Technical
- Relative Strength Index (RSI)
- CYH 81.62
- EYPT 43.03
- Support Level
- CYH $3.01
- EYPT $11.15
- Resistance Level
- CYH $3.25
- EYPT $12.21
- Average True Range (ATR)
- CYH 0.18
- EYPT 0.80
- MACD
- CYH 0.07
- EYPT -0.22
- Stochastic Oscillator
- CYH 93.56
- EYPT 21.68
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.